Stocky turns companies like Monopar Therapeutics Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. Minerva's 72.5 Leadership Alignment score reflects founder-CEO continuity and disciplined capital allocation, but the Value Compounder Score of 55/100 signals unproven profitability. The core vulnerability: reliance on third-party manufacturers for both ALXN1840 and MNPR-101 radiopharmaceuticals creates supply-chain execution risk that could delay clinical milestones or commercialization.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Monopar Therapeutics Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 56/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Monopar Therapeutics Inc. (MNPR) at 56/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Minerva's 72.5 Leadership Alignment score reflects founder-CEO continuity and disciplined capital allocation, but the Value Compounder Score of 55/100 signals unproven profitability. The core vulnerability: reliance on third-p
MNPR's current Stocky Verdict is 56/100, placing it in the "Cautious" band. This composite combines a 55/100 Compounder score, 73/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Monopar Therapeutics Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Monopar Therapeutics Inc. scores 73/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Monopar Therapeutics Inc.'s Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Monopar Therapeutics Inc..
Sign up free and unlock the full analysis on MNPR — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for MNPR in the app.
